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Abstract
We consider the relationship between the target affinity of a monoclonal antibody and its in vivo
potency. The dynamics of the system is described mathematically by a target-mediated drug
disposition model. As a measure of potency, we consider the minimum level of the free receptor
following a single bolus injection of the ligand into the plasma compartment. From the differential
equations, we derive two expressions for this minimum level in terms of the parameters of the
problem, one of which is valid over the full range of values of the equilibrium dissociation constant
KD and the other which is valid only for a large drug dose or for a small value of KD . Both
of these formulae show that the potency achieved by increasing the association constant kon can
be very different from the potency achieved by decreasing the dissociation constant koff . In
particular, there is a saturation effect when decreasing koff where the increase in potency that
can be achieved is limited, whereas there is no such effect when increasing kon . Thus, for certain
monoclonal antibodies, an increase in potency may be better achieved by increasing kon than by
decreasing koff .
Keywords: Pharmacology, efficacy, affinity, target-mediated drug disposition, IgE.
1. Introduction
Since their introduction as clinical agents in the 1980s, monoclonal antibodies (mAbs) have
become one of the fastest growing classes of therapeutic modalities with 24 mAbs currently on the
market in the US [1] and more than 200 in clinical trials. The increasing interest in biologicals
in general, and mAbs in particular, is partly due to their high success rate during preclinical and
clinical development [1]. It has been suggested that an important element that has contributed to
this success is the fact that, compared to small molecules, the pharmacokinetic-pharmacodynamic
(PKPD) properties of mAbs are more amenable to quantitative, mechanistic modelling and sim-
ulation (M&S)-based translation approaches across preclinical and clinical research [2, 3, 4, 5]. A
specific example of this is the implementation of the principles of target-mediated drug disposition
(TMDD) into quantitative pharmacological models to describe and predict PKPD behaviour of
mAbs. Levy [6] introduced the term TMDD to describe the observations that for certain potent
and selective drugs the fraction (relative to the dose) bound to the pharmacological target may
be so high that it influences their disposition, i.e. PK and PD become interdependent. Mager and
Jusko [7] were the first to propose a general PK model for drugs exhibiting TMDD, which has
provided the basis for extensive further studies and development (see for example [8, 9, 10, 11, 5]).
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Figure 1: The TMDD reaction mechanism
Experimental confirmation of TMDD model predictions was provided in a recent elegant study by
Abraham et al. [12], who showed marked differences in interferon (INF)-β PK in wild-type and
type-1 INF α/β receptor knockout mice.
Although originally proposed to describe the effects of extensive drug-target binding in tis-
sues, TMDD has received most interest as a saturable clearance mechanism (due to, for example,
receptor-mediated endocytosis; see [13]) for biologics, specifically mAbs. One specific example of
the impact of mechanism-based PKPD models based on TMDD principles in drug discovery and
development comes from the area of anti-IgE mAbs. The first generation molecule, omalizumab
(Xolair R© [14]) is used for the treatment of allergic asthma and there has been an interest to
develop more potent, second-generation mAbs with improved clinical efficacy profile [2, 4]. Specif-
ically, TMDD models have been used to explore the impact of mAb affinity for IgE in relation to in
vivo potency (the dose required for a given clinical effect). Through a sensitivity analysis, Agoram
et al. [2] predicted that a ten-fold increase in mAb affinity for IgE would result in an approxi-
mately two-fold reduction in dose compared to omalizumab but that further increases in affinity
were not predicted to result in additional potency improvements. In contrast, simulations did
suggest that increased on-rate of mAb binding to IgE could have additional impact on the in vivo
potency [2]. However no formal analysis was presented to underwrite this hypothesis. Similarly,
Sarkar et al. [15] demonstrated the use of mechanistic models for the design of optimal biologic
therapeutics such as GCSF. Therefore, some examples exist in the literature on the exploration
of the affinity-potency relationships using detailed mathematical models of cellular processes, but
these analyses are heuristic in nature. A systematic analysis of how mechanistic TMDD models
can be employed in potency estimation of candidates is not yet available. Inspired by the before-
mentioned case studies and recent examples of how a rigorous mathematical analysis can aid our
understanding of complex pharmacological systems and provide tools to predict essential PKPD
properties of mAbs [16, 10, 13] we explore the behaviour of a TMDD model with respect to the
relationship between the target affinity of the mAb and its in vivo potency.
Section 1 gives the background for this study and section 2 describes the model development
from the reaction mechanism. The mathematical analysis of the resulting kinetic rate equations is
depicted in this section for easy manipulation and understanding of the model. In sections 3 and 4,
the results and discussion of the model dynamics are presented and mathematical expressions
to approximate the potency of the drug are derived here. Section 5 gives a further analysis
and validation of the relationships derived in the previous sections. Finally, the conclusions and
recommendations arising from these studies are given in section 6.
2
2. Model Equations
In this study, a one-compartment model based on the original work of Levy [6] will be employed.
In this investigation, the ligand L (drug) binds reversibly with the receptor R to form a receptor-
ligand complex P as shown in the scheme in Fig. 1. The TMDDmodel assumes a mechanism-based
reaction to explain the drug-receptor interaction. The parameters of the model are the binding
rate constants kon and koff , the receptor turnover and elimination rates kin and kout , and the
elimination rates of the ligand and complex ke(L) and ke(P) . The system is assumed to be initially
at steady state, into which a single bolus infusion L0 of the ligand into the central (plasma)
compartment is made (represented in Fig. 1 by ‘In’).
From the mechanism of the TMDD reaction shown in Fig. 1 the mathematical model can be
derived using the Law of Mass Action giving the differential equations
dL
dt
= −ke(L)L− konLR+ koffP (1)
dR
dt
= kin − koutR− konLR+ koffP (2)
dP
dt
= konLR− koffP − ke(P)P (3)
The steady state of this system is given by L = P = 0, R = kin/kout . Adding the bolus injection
gives the initial conditions
L(0) = L0, R(0) = R0 =
kin
kout
, P (0) = 0. (4)
We non-dimensionalise these equations by defining the dimensionless variables
x =
L
L0
, y =
R
R0
, z =
P
R0
, τ = koutt.
We also define the non-dimensional parameter
µ =
R0
L0
. (5)
This non-dimensionalisation is different from the one used by Peletier and Gabrielsson [10] who
defined the new time variable as τ = konR0t . The reason for this is that later on we want to
explore the limits of kon → 0 and kon → ∞ , and so we do not want kon to be used in the
rescaling of time. We also note that kout must be non-zero for the steady state R0 to exist, and
so this is an obvious choice of parameter to use for the non-dimensionalisation. In terms of these
non-dimensional quantities, equations (1)–(3) become
dx
dτ
= −K1x−K2xy + µK3z (6)
dy
dτ
= 1− y −
K2
µ
xy +K3z (7)
dz
dτ
=
K2
µ
xy − (K3 +K4) z (8)
with initial conditions
x(0) = 1, y(0) = 1, z(0) = 0,
where the dimensionless parameters are defined by
K1 =
ke(L)
kout
, K2 =
konR0
kout
, K3 =
koff
kout
, K4 =
ke(P)
kout
.
The constant term in (7) is derived by using the definition of the steady state R0 in (4). We note
that the six parameters and one initial value (L0 ) of the dimensional equations have been reduced
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Kinetic Constant Value Parameter Value
ke(L) 0.024 day
−1 K1 0.02916
ke(P) 0.201 day
−1 K2 1.93353
kout 0.823 day
−1 K3 1.09356
koff 0.900 day
−1 K4 0.24423
kon 0.592 (nM day)
−1 µ 0.18144
KD 1.520 nM
kin koutR0 nM day
−1
L0 14.8148 nM
R0 2.688 nM
Table 1: Numerical values of the dimensioned and dimensionless constants for IgE mAb omalizumab [2].
to five non-dimensional constants for the non-dimensional equations, which simplifies the model
equations while keeping the essence of the system.
We use parameter values from the IgE mAb omalizumab case study [2] as an example. The
numerical values of the dimensioned and dimensionless parameters for this case are given in Table
1, where we have also included the value of the equilibrium dissociation constant KD = koff/kon .
For the dimensioned parameters, we use these units hereafter without mentioning them specifically.
Using these parameters, the time profile of the ligand, receptor and ligand-receptor complex are
shown in Fig. 2 for a short time (just past the minimum of R) and for a longer time interval in
Fig. 3. Clearly, plots of the non-dimensional quantities x , y and z will be similar but with a
difference scale on the vertical axis.
These numerical results show different phases occurring. Initially, in a very short time, the
receptor R drops down to a low value while the product P shows a corresponding jump. There
is also an initial sharp but small drop in the ligand L . This phase is dominated by the binding
action of the ligand to the receptor resulting in the product. In the next phase, which happens
on a much slower timescale, the receptor and the product gradually increase, while the ligand
continues with a gradual decrease. Finally, the system settles back to its steady state values.
3. Approximation of the Drug Potency – Method 1
In our analysis, the in vivo potency of the drug is defined to be the minimum free receptor level
that can be achieved for a particular dose of the drug. Mathematically, this minimum receptor
level, Rmin , is obtained by finding the minimum point on the receptor-time profile (see Fig. 2(b))
and is therefore defined as the point where the time derivative of R (or y in dimensionless form)
vanishes.
Setting y˙ = 0 in (7) implies that this minimum occurs when
1− y −
K2
µ
xy +K3z = 0,
which gives
y =
µ(1 +K3z)
µ+K2x
.
The problem with this is that we do not know the values of x and z when the minimum occurs,
and so all this gives us is a two-dimensional surface in the three-dimensional phase space on which
the minimum must occur but the position on this surface where the actual minimum occurs for
the given trajectory is not known.
To address this problem, we rewrite equations (6)–(8) in terms of different variables. In partic-
ular, we introduce a non-dimensional form of the total amount of ligand (free and bound) together
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Figure 2: Concentration-time profile for 0 ≤ t ≤ 1 of (a) the free ligand L , and (b) the free receptor R (blue) and
the ligand-receptor complex P (red).
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Figure 3: Concentration-time profile for 0 ≤ t ≤ 20 of (a) the free ligand L , and (b) the free receptor R (blue)
and the ligand-receptor complex P (red).
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Figure 4: Concentration-time profile of (a) the total ligand L + P and (b) the total receptor R + P . Note the
small variation in values on the vertical L+ P -axis.
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with the total amount of receptor (free and bound). Thus, we define
u =
L+ P
L0
= x+ µz
v =
R+ P
R0
= y + z
We now rewrite our equations in terms of the variables u , v and y , giving
u˙ = −K1u− µ(K4 −K1)(v − y) (9)
v˙ = 1− y −K4(v − y) (10)
y˙ = 1− y −
K2
µ
uy + (K2y +K3)(v − y) (11)
with initial conditions
u(0) = 1, v(0) = 1, y(0) = 1.
The concentration-time profile for the total ligand L+P and the total receptor R+P are shown
in Fig. 4.
We assume that the amount L0 of ligand injected is greater than the steady state value of the
receptor R0 so that the parameter µ , which is defined in (5), satisfies µ 1.
As before, we can set y˙ = 0 in (11) giving
1− y −
K2
µ
uy + (K2y +K3)(v − y) = 0.
We note that in this case, we have a quadratic equation for y which has one positive and one
negative solution. The positive solution is given by
y = −
1
2µK2
(
[K2u+ µ(1 +K3 −K2v)]−
√
[(K2u+ µ(1 +K3 −K2v))2 + 4µ2K2(1 +K3v]
)
.
Since we have assumed that µ is small, the first term under the square root will dominate the
second. Thus, taking this first term out of the square root and then expanding the square root
term gives
y =
µ(1 +K3v)
K2u+ µ(1 +K3 −K2v)
+O(µ3). (12)
Of course, we still have the problem that this formula for y involves the variables u and v .
However, the advantage of working with equations (9)–(11) is that the variables u and v evolve
on a much slower timescale than y . To see this, we note that
u˙(0) = −K1, v˙(0) = 0, y˙(0) = −
K2
µ
.
Provided that µK1/K2 = ke(L)/(konL0) is small, which is the case for the parameter values we
are considering, then the derivative of y at time zero is much greater than the corresponding
derivatives of u and v , and hence y will initially change at a much faster rate than u and v , as
can be seen from Figs 2 and 4. Indeed, the variables in Fig. 4 do not show the initial sharp change
that can be observed for R (or equivalently y ) in Fig. 2.
During this initial fast phase, u and v remain approximately constant while y quickly decreases
to its minimum and so we can approximate this minimum by setting u = u(0) = 1 and v = v(0) =
1. Substituting these values into (12) and ignoring the higher order terms gives an approximation
to the minimum value of y as
y
(1)
min =
µ(1 +K3)
K2 + µ(1 +K3 −K2)
. (13)
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Converting this expression back to the dimensional variables, we obtain an approximation for the
minimum of R as
R
(1)
min =
R0(koff + kout)
kon(L0 −R0) + koff + kout
. (14)
Looking at the limiting cases, we see that varying kon gives
lim
kon→0
R
(1)
min = R0, lim
kon→∞
R
(1)
min = 0. (15)
Similarly, varying koff gives
lim
koff→∞
R
(1)
min = R0, lim
koff→0
R
(1)
min =
R0kout
kon(L0 −R0) + kout
, (16)
We note that in the limit as KD = koff/kon →∞ there is no reaction between the ligand and
the receptor and hence no product is formed. Thus, R remains at its steady state value R0 and
so we have obtained the correct limit in this case.
In the alternative case when KD = koff/kon → 0, we note that increasing kon results in the
minimum level of the receptor decreasing to zero, while decreasing koff results in the minimum
receptor level decreasing to a non-zero level.
We note in passing that the formula for R
(1)
min can be expressed in terms of the single parameter
(koff + kout)/kon for given L0 and R0 and so an increase in kon will have the same effect as a
corresponding decrease in koff + kout . However, kout is not a constant over which we have any
control, and so this observation is not particularly helpful in practice.
4. Approximation of the Drug Potency – Method 2
In the previous section, we worked with the dimensionless variables for the total ligand (u) ,
total receptor (v) and free receptor (y) . We now consider a similar approach using instead the
dimensionless variables for the total ligand (u) , free receptor (y) and product (z) . In this case,
the condition for the minimum of y (i.e. y˙ = 0) gives
µ(1− y)−K2(u− µz)y + µK3z = 0,
which is linear in y . Solving this equation for y we obtain
y =
µ(1 +K3z)
K2u+ µ(1−K2z)
.
As before, we note that u remains approximately constant during the initial fast phase and so
we again take u = 1. However, z changes rapidly during the initial phase, as does y , and so we
cannot use the initial value of z . The assumption used previously that v = 1 implies that y+z = 1
or z = 1− y . Now at the minimum point, if we assume that y = O(µ) , then z = 1−O(µ) at this
point. Since µ is assumed to be small, we simply take z = 1 as the leading order approximation.
With these two assumptions, we obtain an approximation for the minimal receptor level as
y
(2)
min =
µ(1 +K3)
K2 + µ(1−K2)
, (17)
which is very similar, but not quite the same, as the previous approximation y
(1)
min given in (13).
Converting back to the original coordinates gives
R
(2)
min =
R0(kout + koff)
kon(L0 −R0) + kout
. (18)
It is easily verified that y
(2)
min = y
(1)
min +O(µ
2) . We also note that
lim
kon→∞
R
(2)
min = lim
kon→∞
R
(1)
min = 0, (19)
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and that
lim
koff→0
R
(2)
min = lim
koff→0
R
(1)
min =
R0kout
kon(L0 −R0) + kout
, (20)
and so the limiting values for the two approximations R
(1)
min and R
(2)
min as KD = koff/kon → 0 are
the same. However, in the other limit with KD = koff/kon →∞ , we find that
lim
kon→0
R
(2)
min = R0
(
1 +
koff
kout
)
, lim
koff→∞
R
(2)
min =∞.
Thus, the correct values are not obtained in this limit. This is expected since we assumed above
that ymin = O(µ) , which in turn implies that (1 +K3)/K2 = O(1). When koff/kon is large, then
K3/K2 is also large and so this condition is violated and the approximation is not valid.
The main assumption that we use in deriving (18) is that the minimum value of y is small. One
way that this can be achieved is to assume that µ = R0/L0 is small. However, this is not the only
condition that can give a small minimum value for y . The small minimum value is obtained as a
consequence of the reaction between L and R , which produces the product P , happening on a
much faster timescale than the other dynamic processes, and from the non-dimensional equations
(6)–(8), we can see that the reduction of y will happen on a fast timescale if the product term
K2xy/µ is larger than the other terms in (7). The coefficient K2/µ = konL0/kout will be larger
than the other coefficients if konL0 is large relative to kout and koff . Another requirement is that
x should not be depleted too quickly by elimination relative to the reaction rate, and this requires
that ke(L) is small relative to konL0 . Clearly, these conditions can be fulfilled in two ways, namely
by L0 being large relative to kout , koff and ke(L) (as we have already considered) or by kon being
large relative to kout , koff and ke(L) (with no corresponding requirement that L0 also be large).
In this second case, the results given by (19) and (20) also hold. We note that even for a large
(fixed) value of L0 , if KD becomes sufficiently large, then konL0 will no longer be large relative
to koff and so this approximation fails.
5. Validation and Further Analysis of the Approximations
We now compare these predicted approximate values with numerical values obtained from the
differential equations. We use the values of the constants from the omalizumab case study, as
given in Table 1. Since µ is quite small, the second approximation will be valid in this case.
Solving the differential equations numerically gives the true minimum of R to be Rmin = 0.5811.
Our two approximations give values of
R
(1)
min = 0.5203, R
(2)
min = 0.5787,
from which we can see that the second approximation gives a better result
It is also interesting to consider these approximations over a range of values of KD = koff/kon .
In the omalizumab study we have the parameter values koff = 0.9 and kon = 0.592, hence
KD = 1.52. To make it easier to compare results for varying either kon or koff , we first fix
kon = 0.592 and vary koff via koff = 0.592KD and then we fix koff = 0.9 and vary kon = 0.9/KD .
The resulting Rmin data points from the numerical simulation of the differential equations and
approximation curves R
(1)
min and R
(2)
min are plotted as functions of the variable KD in Fig. 5. This
illustrates that R
(1)
min is a good approximation for all values of KD . For small values of KD ,
the approximation R
(2)
min is better than R
(1)
min , but for larger values of KD , the approximation
R
(2)
min starts to fail as expected. For koff = 0 and kon = 0.592, we have the approximation
R
(1)
min = R
(2)
min = 0.2765, while the numerical simulation gives Rmin = 0.3014. For koff = 0.9 and
kon →∞ , we have both the simulation and the approximations converging to zero.
It can be seen that the approximation R
(1)
min corresponds well to the results obtained by simu-
lation over the whole range of KD values, while the approximation R
(2)
min is a good approximation
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Figure 5: The minimal value of R as a function of KD with (a) KD plotted on a log scale for a wide range of
KD values and (b) KD plotted on a linear scale for KD small. In both plots, the red solid curve (R
(1)
min ) and
dash-dotted curve (R
(2)
min ) and points ∗ (numerical simulation) are for koff = 0.9 and kon = 0.9/KD . Similarly,
the blue solid curve (R
(1)
min ) and dashed curve (R
(2)
min ) and points • (numerical simulation) are for kon = 0.592
andkoff = 0.592KD .
when Rmin/R0 is small, which occurs when either L0 or kon is large. Thus the analytical expres-
sions capture the relationship between the potency (Rmin ) and the affinity constants (koff and
kon ) very well.
Another way to view the expression for R
(1)
min is by plotting it as a function of the two variables
log10(koff) and log10(kon) as shown in Fig. 6. The R
(1)
min contours of this surface are shown in
Fig. 7, while the contours with koff and kon constant are shown in Figs 8 and 9 respectively. We
note in Fig. 7 that when log10(koff) is positive, the contours of R
(1)
min appear to be approximately
straight lines of slope one. On the other hand, when log10(koff) is less than −1, the contours are
approximately horizontal lines. This can be explained as follows.
If koff  kout , then koff will make a negligible contribution to the numerator and the denom-
inator of R
(1)
min and so we can set it to zero, giving
R
(1)
min ≈
R0koff
kon(L0 −R0) + koff
=
R0KD
L0 −R0 +KD
, for koff  kout.
Thus, in this case, R
(1)
min depends only on the single parameter KD = koff/kon and not separately
on koff and kon . If we now consider a contour which corresponds to a constant value of Rmin = Rc ,
for some given constant Rc , then we can solve the equation R
(1)
min = Rc for KD giving
KD =
Rc(L0 −R0)
R0 −Rc
, for koff  kout.
Taking logs, we then find that
log10(kon) = log10(koff)− log
(
Rc(L0 −R0)
R0 −Rc
)
, for koff  kout
and so the relationship between log10(koff) and log10(kon) is linear with slope one, as seen in Fig.
7, for koff sufficiently large.
At the other extreme, when koff  kout , then koff will be negligible compared to kout and so,
setting it to zero, we obtain
R
(1)
min ≈
R0kout
kon(L0 −R0) + kout
, for koff  kout.
In this case, setting R
(1)
min = Rc and solving for kon , we obtain
kon =
kout(R0 −Rc)
Rc(L0 −R0)
, for koff  kout
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Figure 6: Plot of R
(1)
min given by (14) as a function of log10(koff) and log10(kon) .
Figure 7: Contours of the surface shown in Fig. 6 for constant values of Rmin .
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Figure 8: Contours of the surface shown in Fig. 6 for constant values of koff .
Figure 9: Contours of the surface shown in Fig. 6 for constant values of kon .
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and clearly this expression for kon does not depend on koff (since we set it to zero!) and so
log10(kon) is a constant.
Thus, the contours asymptote to a constant as log10(koff) → −∞ (koff → 0) and asymptote
to a straight line of slope one as log10(koff)→∞ (koff →∞). The in-between region, when koff
and kout are of similar order, gives the curve that joins these two straight lines.
We are now able to derive further information on the effect of varying koff or kon on Rmin .
When koff is large relative to kout , we have seen that R
(1)
min effectively depends only on the single
parameter KD , in which case increasing kon by a factor of α will have the same effect on Rmin
as decreasing koff by a factor of α . However, when koff is either small or of similar magnitude
to kout (as is the case for omalizumab), then increasing kon by a factor of α will have a much
greater effect than reducing koff by a factor of α .
We note that over the whole range of values of log10(koff) to move from one contour in Fig. 7 to
a lower one can always be achieved by a relatively small increase in log10(kon) . However, moving
to a lower contour by decreasing log10(koff) can easily be achieved with a relatively small decrease
when log10(koff) is large, but requires a much larger decrease for smaller values of log10(koff) ,
and for smaller values still, it is not possible to move to a lower contour by decreasing log10(koff) .
This is consistent with the results shown in Fig. 5.
Finally, we consider what increase in kon , or decrease in koff , is required to reduce Rmin by a
factor of two (which correponds to increasing the efficacy from say 90% to 95%). We suppose that
R
(1)
min = Rc when kon = k
0
on and that R
(1)
min = Rc/2 when kon = k
1
on . This gives the two equations
Rc =
R0(koff + kout)
k0on(L0 −R0) + koff + kout
,
Rc
2
=
R0(koff + kout)
k1on(L0 −R0) + koff + kout
.
Eliminating Rc from these equations and solving for k
1
on gives
k1on = 2k
0
on +
koff + kout
L0 −R0
, (21)
and so we conclude that to reduce Rmin by a factor of two, kon has to be more than doubled,
since the second term on the right of (21) is positive.
If we define K0D = koff/k
0
on and K
1
D = koff/k
1
on , then from (21) we find that
K1D =
1
2
K0D
(
2k0on(L0 −R0)
2k0on(L0 −R0) + koff + kout
)
.
Since the term in the brackets is less than one, clearly KD must be reduced by a factor greater
than two in order to reduce Rmin by a factor or two, which is consistent with the above statement
regarding kon .
A similar calculation where koff is varied rather than kon gives
k1off =
1
2
k0off −
1
2
kout −
(k0off + kout)
2
4kon(L0 −R0) + 2(k0off + kout)
. (22)
In this case, to reduce Rmin by a factor of two, koff must be reduced by more than a factor of
two. Moreover, it is quite possible that this formula gives k1off < 0, which of course implies in such
a case that it is not possible to reduce Rmin by a factor of two by reducing koff , which we have
already noted above.
If we define K˜0
D
= k0off/kon and K˜
1
D
= k1off/kon , then from (22) we have that
K˜1
D
=
1
2
K˜0
D
−
kout
2kon
−
(k0off + kout)
2
kon[4kon(L0 −R0) + 2(k0off + kout)]
=
1
2
K˜0
D
−
k
2
−
(K˜0
D
+ k)2
4(L0 −R0) + 2(K˜0D + k)
where k = kout/kon . The comments above regarding koff apply also to K˜D .
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6. Discussion and Conclusion
The main objective of the work presented in this paper was to explore the TMDD model
through a rigorous mathematical analysis with regards to the relationship between the target
affinity of a mAb versus its in vivo potency. In our experience, this topic invariably gets raised in
mAb drug discovery and development programs, mainly because the maximum dose for routine
clinical use in patients is typically more stringently constrained for mAbs compared to small
molecules due to non-oral route of administration, formulation complexities and cost of goods,
and because increasing the affinity of a mAb is a time-consuming process.
The first, perhaps obvious, conclusion of our analysis is that for a given dose (L0 ) the minimum
value of free target (Rmin ) can be decreased (equivalent to increasing in vivo potency) by increasing
kon or by decreasing koff . While this conclusion may be obvious, what may not be so apparent is
that there is a significant difference in the minimum receptor obtained when KD is reduced either
by reducing koff or by increasing kon . We note from (15) that as kon → ∞ , then R
(1)
min → 0,
whereas from (16), as koff → 0, then R
(1)
min tends to a non-zero value, with the same limits being
obtained from R
(2)
min , as already noted. Thus, we have a saturation effect when decreasing koff ,
in that further reductions in the value of koff will only yield limited reductions in Rmin , whereas
there is no such saturation when increasing kon , so that Rmin is consistently reduced for increasing
values of kon .
We see from (16) and (20) that the limiting value of Rmin as koff → 0 in both cases is given
by
lim
koff→0
R
(1)
min = lim
koff→0
R
(2)
min =
kinkout
kon(koutL0 − kin) + k2out
,
where we have substituted R0 = kin/kout . Thus, we can see that this saturation level will be
reduced by increasing kon or L0 . Theoretically, the saturation level could also be reduced by
decreasing kin or by increasing kout .
This sheds new light on our previous work [2] in which, through simulations, we predicted
that the maximum increase in potency that could be achieved with an anti-IgE antibody by only
reducing the koff would be approximately two-fold compared to omalizumab, and that this would
be achieved with a five-to-ten-fold increase in affinity. Clinical data reported subsequently by
Putnam et al. [4] on the high-affinity anti-IgE mAb, HAE1, were consistent with this prediction,
since it was shown that HAE1 achieved an approximately two-fold improvement in in vivo potency
compared to omalizumab, whereas it displayed a more than twenty-fold higher affinity for IgE.
Interestingly, the data presented in [4] show that the affinity improvement of HAE1 compared to
omalizumab was entirely driven by a reduction in koff , consistent with our prediction that this
parameter is associated with a saturation effect regarding its impact on in vivo potency.
As far as we are aware there is no experimental data to support our hypothesis that such
a saturation effect does not exist for kon , but our analysis does suggest that a mAb potency
optimisation strategy focused on increasing kon rather than decreasing koff could be advantageous.
Currently, the majority of marketed mAbs and those in clinical development are IgE’s of about
150 kDa size and their kon values are generally uniform and limited by their size. However,
even if rational optimisation of kon is currently not experimentally possible, our analysis indicates
that between two antibodies of sufficiently low koff (in the saturation effect range), one antibody
with a higher kon is more potent even if it may have higher koff and hence, potentially higher
overall KD . While this conclusion may already have been derived in an empirical manner within
certain areas of biologics discovery (especially with the extensive research into highly labile targets
such as interleukins) we have provided the first systematic quantitative analysis that can guide
rational optimisation of mAbs within the context of the TMDD framework. For example, in
recent years, significant efforts have been put into the development of novel human and non-human
scaffolds (‘nanobodies’) of much smaller size (see [17, 18]). Although currently these efforts appear
to be mainly motivated by predicted improvement of tissue penetration, systemic stability and
preferential cleft recognition [19], an intriguing question that follows on from the present analysis
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is whether nanobodies could display faster kon rates due to their smaller size and therefore may
be more amenable to optimisation of in vivo potency compared to traditional mAbs.
It should be pointed out that an important assumption in our analysis is that L0 must be
significantly larger than R0 . Of course this is not a rigorous statement, but the important criterion
is that the parameter µ = R0/L0 must be small, as was assumed in the mathematical analysis. We
have shown that the value of µ = 0.18144 for the IgE mAb omalizumab is sufficiently small for the
analysis to work well. However, while this assumption may generally hold true for blocking and
neutralising antibodies, it may not be true for agonists and in cases where pharmacological effect
may be exerted at low levels of target occupancy. Therefore, our conclusions may not be valid
in those cases. However, we do not believe this greatly limits applicability of the simplification
we have provided, since in the cases where the underlying assumption is violated, lower doses are
only required for clinical efficacy and therefore affinity requirements tend to be less stringent. It
should also be noted that this analysis is only applicable for a rather simple antigen-antibody
system which interacts without diffusion barriers, avidity effects, and other complexities. These
complicating factors should be considered to be able to extend the model to more realistic drug
discovery situations.
In conclusion, our analysis of the TMDD model has provided a mathematical framework that
relates intrinsic pharmacological and pharmacokinetic properties of mAbs to their in vivo potency.
The finding that the greatest potency improvements can be achieved, at least in theory, through
modulation of kon could provide a basis for new strategies to drive the discovery of a new generation
of mAbs. The simple formula we have provided can also substantially reduce the need for complex
PKPD analyses resources to get an initial estimate of required affinity at the lead optimisation
stage.
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